Stockwinners Market Radar for May 27, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Amazon's (AMZN) computing unit AWS is in talks with Italy to invest billions of euros in the expansion of its data center business in the country as part of the tech giant's effort to boost its cloud offer in Europe, Reuters' Elvira Pollina, Valentina Za and Supantha Mukherjee report, citing four people familiar with the matter. Discussions between parties over the size and the location of the investment are ongoing, according to the sources, with one of them saying Amazon Web Service is considering expanding its current site in Milan or building a new one. 2. Meta Platforms (META) has added safety features to its misinformation tracking tool CrowdTangle for use during European Parliament elections in an attempt to allay EU concerns that triggered an investigation last month into the impact of its decision to phase out the tool, Reuters' Foo Yun Chee reports. The U.S. social media platform last week said candidates for next month's polls will be shown a notification at the top of their feed in Facebook and Instagram on how to protect themselves and their accounts. 3. Shares of Walmart (WMT) soared 7% to a new high on Thursday, their biggest jump since the start of the pandemic. It was the best performer in the S&P 500 that day, and has climbed over 20% this year alone. It looks like the stock isn't done yet, Teresa Rivas says in this week's edition of Barron's. As the company's most recent results show, there's more runway ahead as its strategy accelerates, the author adds. Walmart is expected to rapidly boost its earnings over the coming years, the publication says. 4. Warner Bros' (WBD) "Furiosa" won this year's Memorial Day weekend with a $32M debut for the four-day stretch. This was also the worst Memorial Day number 1 opener since "Casper" almost 30 years ago in 1995, according to Comscore. "Furiosa" sports a B+ CinemaScore from audiences. 5. Keurig Dr Pepper (KDP), Dell Technologies (DELL), Marvell Technology (MRVL), Salesforce (CRM), and AMD (AMD) saw positive mentions in this week's edition of Barron's.

06:42 EDT Vera Therapeutics presents data from Phase 2b ORIGIN trial of atacicept - Vera Therapeutics announced data presentations from its Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy, showing that atacicept stabilized kidney function through 72 weeks and led to rapid improvements in hematuria. These data were presented at the 61st European Renal Association Congress being held in Stockholm. "For the first time in this field, we presented 72-week data from our Phase 2b ORIGIN trial showing stable kidney function over the duration of treatment. In addition, we presented data showing that atacicept leads to hematuria resolution in significantly more patients compared with placebo. The impact on hematuria was seen as early as 4 weeks after treatment initiation, which could have important implications for patients with acute kidney inflammation. The evolving atacicept data package supports our belief that atacicept may offer comprehensive disease modification to patients with IgAN," said Marshall Fordyce, Founder and CEO of Vera Therapeutics. "We look forward to presenting the full 96-week data from the Phase 2b ORIGIN trial, which are expected in the fourth quarter of this year." Participants who received atacicept for 72 weeks had stable eGFR, as well as consistent and sustained reductions in Gd-IgA1, hematuria and UPCR. Participants who switched from placebo to atacicept also demonstrated stable eGFR, as well as similar reductions in Gd-IgA1, hematuria, and UPCR as compared with participants randomized to atacicept during the first 36 weeks of the trial. The cumulative safety profile of atacicept was similar to the randomized period, with a 91% retention rate through 72 weeks. The company believes these data support the potential for atacicept to offer long-term, comprehensive IgAN disease modification and support the ongoing pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN.

06:37 EDT Novartis presents latest Phase III Fabhalta data in C3 glomerulopathy - Novartis presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta, or iptacopan, at the late-breaking clinical trials session of the European Renal Association Congress. Patients treated with Fabhalta in addition to supportive care achieved a 35.1% reduction in proteinuria at 6 months when compared to placebo on top of supportive care. In many kidney diseases, proteinuria reduction is an increasingly recognized surrogate marker correlating with delaying progression to kidney failure. Additional data on the secondary endpoint of estimated glomerular filtration rate, a measure of kidney function, showed a numerical improvement of +2.2 mL/min/1.73 m2 over 6 months with Fabhalta compared to placebo. The study also showed Fabhalta has a favorable safety profile with no new safety signals. The APPEAR-C3G study continues with an additional 6-month, open-label period following the 6-month double-blind period, in which all patients receive Fabhalta, including those previously receiving placebo2,3. These data will be presented at an upcoming medical meeting when available. At ERA, Novartis is also presenting new data across its rare disease portfolio, including results for investigational atrasentan in IgA nephropathy from the 36-week interim analysis of the Phase III ALIGN study, additional data for Fabhalta in IgAN from the 9-month interim analysis of the Phase III APPLAUSE-IgAN study, long-term 33-month efficacy and safety data for Fabhalta in C3G from the Phase II extension study, 1-year Phase I/II data for investigational zigakibart in IgAN, and data from real-world studies in C3G and atypical hemolytic uremic syndrome.